Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Key Clinical Message Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma. Lenalidomide has been developed as the derivative o...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2018-02, Vol.6 (2), p.391-394
Main Authors: Shimokihara, Kota, Kawahara, Takashi, Suzuki, Taisei, Mochizuki, Taku, Takamoto, Daiji, Teranishi, Jun‐ichi, Miyoshi, Yasuhide, Yumura, Yasushi, Yao, Masahiro, Uemura, Hiroji
Format: Article
Language:English
Subjects:
Case Report
Case Reports
Castration‐resistant prostate cancer
Immunotherapy
lenalidomide
Prostate cancer
Targeted cancer therapy
thalidomide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Key Clinical Message Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma. Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.1328